Market Closed -
Japan Exchange
07:00:00 12/09/2024 BST
5-day change
1st Jan Change
8,189.00 JPY
+0.40%
-1.18%
+54.83%
This article is reserved for members
Not a member ?
Free registration
Jefferies Adjusts Otsuka Holdings' Price Target to 9,700 Yen From 9,300 Yen, Keeps at Buy
08-27
MT
Jefferies Adjusts Otsuka Holdings' Price Target to 9,300 Yen From 8,600 Yen, Keeps at Buy
08-19
MT
Otsuka's Profit Up 5% in Fiscal H1
08-02
MT
Global markets live: Shell, Chevron, Boeing, Walt Disney, Qualcomm...
08-01
Japan's Otsuka Pharma to pay up to $1.1 bln to acquire Jnana Therapeutics
08-01
RE
Otsuka Holdings Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2024
08-01
CI
Otsuka Holdings Co., Ltd. Announces Second Quarter-End Dividend for the Six Months Ended June 30, 2024, Payable on September 2, 2024
08-01
CI
Transcript : Otsuka Holdings Co., Ltd., Q2 2024 Earnings Call, Aug 01, 2024
08-01
Otsuka Holdings Co., Ltd. announces an Equity Buyback for 10,000,000 shares, representing 1.84% for ¥50,000 million.
08-01
CI
Otsuka Holdings Co., Ltd. authorizes a Buyback Plan.
07-30
CI
Jefferies Adjusts Otsuka Holdings' Price Target to 8,600 Yen From 8,100 Yen, Keeps at Buy
07-29
MT
Nikkei Rises Ends Eight-Session Losing Streak on Monetary Tightening Bets
07-29
MT
Otsuka Revises H1 Financial Outlook Upward
07-29
MT
Otsuka Holdings Co., Ltd. Revises Consolidated Earnings Guidance for the First Half Ended June 30, 2024
07-26
CI
Jefferies Adjusts Otsuka Holdings' Price Target to 8,100 Yen From 7,800 Yen, Keeps at Buy
07-10
MT
Indivior shares dive on profit warning, dropping of schizophrenia drug (July 9)
07-09
RE
UK Pharmaceutical Trade Group Slams Novartis, Three Others for Breaches
07-05
MT
Otsuka and Lundbeck's PTSD Treatment Moves Forward as FDA Accepts New Drug Application
06-26
MT
Lundbeck and Otsuka Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder
06-25
CI
Otsuka Holdings Co., Ltd. Provides Earnings Guidance for the Year 2026
06-07
CI
Correction: Otsuka Pharmaceutical's PTSD Treatment Candidate Sees Statistically Significant Results in Two Out of Three Trials
05-30
MT
Japanese Shares Close Lower as JGB Yields Hit 12-Year High
05-29
MT
Otsuka Pharmaceutical's PTSD Treatment Candidate Fails to Meet Primary Endpoint in Phase 3 Trial
05-29
MT
Jefferies Adjusts Otsuka Holdings' Price Target to 7,800 Yen From 7,400 Yen, Keeps at Buy
05-23
MT
Otsuka Holdings' Attributable Profit Soars 26% in Fiscal Q1
05-22
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Otsuka Holdings Co, Ltd. is a holding company organised around 4 areas of activity:
- manufacture and sale of pharmaceutical products (65.2% of sales): prescription drugs and intravenous solutions mainly for the treatment of central nervous system disorders, cancer, cardiovascular, gastrointestinal and ophthalmic diseases. In addition, the group sells diagnostic products and medical devices;
- manufacture and sale of nutraceutical products (25.1%): functional foods and beverages, OTC products, nutritional supplements;
- production of mineral waters, beverages and foods (2.1%);
- other (7.5%): manufacture of functional chemicals and fine chemicals, provision of logistics services, manufacture of electronic products, etc.
Net sales by source of income are divided between sales of products (93.8%), sales of licences and royalties (1.8%) and other (4.4%).
Net sales are distributed geographically as follows: Japan (43.2%), North America (34%),
More about the company
Last Close Price
8,156.00 JPY
Average target price
8,259.09 JPY
Spread / Average Target
+1.26%
Consensus
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1